Wafra Investment Advisory Group Has Lowered Jp Morgan Chase & Co. (JPM) Stake By $7.72 Million, 0 Analysts Covering Abaxis (ABAX)

June 19, 2017 - By Dolores Ford

Wafra Investment Advisory Group Inc decreased Jp Morgan Chase & Co. (JPM) stake by 26.59% reported in 2016Q4 SEC filing. Wafra Investment Advisory Group Inc sold 89,825 shares as Jp Morgan Chase & Co. (JPM)’s stock declined 6.04%. The Wafra Investment Advisory Group Inc holds 247,978 shares with $21.40 million value, down from 337,803 last quarter. Jp Morgan Chase & Co. now has $311.59B valuation. The stock rose 2.23% or $1.92 reaching $88.1. About 9.99 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since June 19, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

Among 8 analysts covering Abaxis (NASDAQ:ABAX), 0 have Buy rating, 3 Sell and 5 Hold. Therefore 0 are positive. Abaxis had 13 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, July 23 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Underperform” rating by Credit Suisse given on Thursday, February 4. The firm has “Underperform” rating given on Wednesday, October 21 by Bank of America. CL King initiated the shares of ABAX in report on Friday, April 1 with “Neutral” rating. Northcoast downgraded Abaxis Inc (NASDAQ:ABAX) on Wednesday, November 30 to “Neutral” rating. The firm earned “Hold” rating on Friday, April 1 by Canaccord Genuity. Canaccord Genuity maintained the shares of ABAX in report on Thursday, October 29 with “Hold” rating. The firm has “Hold” rating given on Friday, January 27 by Stifel Nicolaus. The stock has “Sell” rating by Feltl & Co on Friday, July 22. The stock of Abaxis Inc (NASDAQ:ABAX) has “Hold” rating given on Thursday, November 12 by Canaccord Genuity. See Abaxis Inc (NASDAQ:ABAX) latest ratings:

27/01/2017 Broker: Stifel Nicolaus Rating: Hold Old Target: $50 New Target: $48 Maintain

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The company has market cap of $1.16 billion. The Firm markets and sells its products around the world through independent distributors and direct sales force. It has a 35.96 P/E ratio. The Company’s divisions are the medical market and the veterinary market.

About 48,144 shares traded. Abaxis Inc (NASDAQ:ABAX) has risen 7.18% since June 19, 2016 and is uptrending. It has underperformed by 9.52% the S&P500.

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.17, from 1.24 in 2016Q3. It fall, as 13 investors sold Abaxis Inc shares while 43 reduced holdings. 15 funds opened positions while 45 raised stakes. 22.45 million shares or 0.53% less from 22.57 million shares in 2016Q3 were reported. Neuberger Berman Gp Limited Liability holds 1.16M shares. Wesbanco Bancshares Inc invested in 0.02% or 7,300 shares. Capstone Asset Management Com has invested 0.01% of its portfolio in Abaxis Inc (NASDAQ:ABAX). Ubs Asset Management Americas Incorporated reported 0% of its portfolio in Abaxis Inc (NASDAQ:ABAX). Vanguard Incorporated invested in 1.92 million shares or 0.01% of the stock. Commercial Bank Of America De has invested 0% in Abaxis Inc (NASDAQ:ABAX). Ameriprise Fin holds 0.01% of its portfolio in Abaxis Inc (NASDAQ:ABAX) for 227,245 shares. Products Prtn reported 24,300 shares stake. 593,785 are held by Wells Fargo Mn. Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Abaxis Inc (NASDAQ:ABAX). Old Mutual Investors (Uk) Ltd invested in 0% or 1,911 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 598 shares for 0% of their portfolio. Gotham Asset Mngmt Limited Liability Com invested in 4,801 shares. Comerica Bancorp accumulated 24,745 shares. Swiss National Bank & Trust stated it has 37,100 shares or 0% of all its holdings.

Since February 1, 2017, it had 0 insider buys, and 4 selling transactions for $799,242 activity. Another trade for 650 shares valued at $31,766 was made by Henkel Achim on Friday, May 26. $204,472 worth of Abaxis Inc (NASDAQ:ABAX) shares were sold by BASTIANI RICHARD. SINGH PRITHIPAL had sold 3,000 shares worth $150,000.

Wafra Investment Advisory Group Inc increased Merck & Co. Inc. (NYSE:MRK) stake by 133,889 shares to 367,719 valued at $21.65 million in 2016Q4. It also upped Wal (NYSE:WMT) stake by 128,817 shares and now owns 135,497 shares. Gulfport Energy Corp (NASDAQ:GPOR) was raised too.

Investors sentiment decreased to 0.82 in Q4 2016. Its down 0.15, from 0.97 in 2016Q3. It is negative, as 69 investors sold JPM shares while 807 reduced holdings. 166 funds opened positions while 553 raised stakes. 2.60 billion shares or 2.27% more from 2.54 billion shares in 2016Q3 were reported. Wellcome Tru Ltd (The) As Trustee Of The Wellcome Tru invested in 4.70M shares or 8.11% of the stock. Reilly Finance Advisors Limited Liability holds 3,792 shares. 31,795 were reported by Cohen Lawrence B. Mirador Partners Lp holds 1.83% or 26,408 shares. Moreover, Blb&B Advsrs Limited Liability Company has 1.89% invested in JPMorgan Chase & Co. (NYSE:JPM) for 125,718 shares. Cincinnati Specialty Underwriters invested 8.79% in JPMorgan Chase & Co. (NYSE:JPM). Wells Fargo And Com Mn holds 25.64 million shares. Norinchukin Natl Bank The has invested 0.28% in JPMorgan Chase & Co. (NYSE:JPM). Moreover, Liberty Mutual Group Asset Mgmt has 0.8% invested in JPMorgan Chase & Co. (NYSE:JPM) for 259,261 shares. Horizon Kinetics Ltd Liability Company stated it has 0.02% in JPMorgan Chase & Co. (NYSE:JPM). Capital holds 1.78% or 14.31 million shares in its portfolio. Coe Capital Mngmt Limited Liability Com invested 3.71% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Gofen Glossberg Limited Liability Company Il reported 853,384 shares. Earnest Ltd Liability Corporation reported 0.26% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Saturna Cap invested 0.05% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM).

Among 25 analysts covering JPMorgan Chase & Co (NYSE:JPM), 13 have Buy rating, 2 Sell and 10 Hold. Therefore 52% are positive. JPMorgan Chase & Co had 52 analyst reports since July 21, 2015 according to SRatingsIntel. The company was upgraded on Friday, January 15 by Atlantic Securities. As per Tuesday, August 25, the company rating was upgraded by Credit Agricole. The firm has “Buy” rating given on Wednesday, October 7 by Jefferies. Berenberg initiated the shares of JPM in report on Wednesday, July 13 with “Sell” rating. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Underperform” rating by Portales Partners on Monday, February 22. The firm has “Neutral” rating given on Monday, January 18 by UBS. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Buy” rating by Argus Research on Friday, January 15. The rating was downgraded by Goldman Sachs to “Neutral” on Monday, January 11. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Outperform” rating given on Wednesday, October 14 by Keefe Bruyette & Woods. The rating was downgraded by Ertse Group to “Hold” on Monday, April 25.

Since January 13, 2017, it had 0 insider buys, and 10 sales for $21.13 million activity. Another trade for 42,083 shares valued at $3.54 million was made by Zames Matthew E on Friday, January 13. Another trade for 13,072 shares valued at $1.09 million was sold by Lake Marianne. 12,986 shares were sold by BACON ASHLEY, worth $1.09 million on Friday, January 13. $3.01M worth of JPMorgan Chase & Co. (NYSE:JPM) shares were sold by Erdoes Mary E.. $5.51 million worth of JPMorgan Chase & Co. (NYSE:JPM) shares were sold by Smith Gordon. Petno Douglas B had sold 6,728 shares worth $566,195 on Friday, January 13. 40,433 shares valued at $3.40M were sold by Pinto Daniel E on Friday, January 13.

Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on July, 13. They expect $1.63 earnings per share, up 5.16% or $0.08 from last year’s $1.55 per share. JPM’s profit will be $5.76 billion for 13.51 P/E if the $1.63 EPS becomes a reality. After $1.65 actual earnings per share reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts -1.21% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: